MEET YOUR NEW AI CLINICAL ASSISTANT /// GET EARLY ACCESS
Bringing the power of data and artificial intelligence to healthcare.
the discovery of novel targets
the effectiveness of treatments
potentially life-saving clinical trials
multiple diseases earlier
We can assist pharmaceutical and biotech companies with better drug development.
Learn MoreWe have built a proprietary Platform to make data accessible and deploy AI at scale.
Learn MoreThrough our scientific publications and research projects, we are accelerating and transforming personalized patient care.
View All Publications
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities
Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.
A Pan-cancer Organoid Platform for Precision Medicine
Showcasing a robust pan-cancer tumor organoid (TO) platform, revealing genomic/transcriptome fidelity of TO culture from >1,000 patients. We demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity in drug responses with applicability across solid cancers.
Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA
Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.
Tempus acquired Mpirik, a cardiology-focused healthcare technology company specializing in data-driven patient screening, automated care coordination, and clinical research, to help accelerate the company’s mission to identify patients with undiagnosed and undertreated cardiovascular disease.
READ PRESS RELEASEThe multi-year, strategic collaboration with Pfizer aims to further AI and machine learning-driven efforts in therapeutic development and more precisely gather insights that will inform novel drug discovery and development in oncology.
READ PRESS RELEASETempus AI Advisors Program (TAAP) is a platform that provides investigators access to the company’s multimodal database to enable development of novel clinical, molecular, and imaging-based algorithms to improve clinical care. TAAP fosters additional research to identify novel clinical biomarkers and use them to develop algorithmic diagnostics that Tempus will validate and make available to physicians for clinical care.
READ PRESS RELEASEThis is the future of healthcare.